Keywords: ketamine, alcohol withdrawal, ethanol (PubMed Search)
Posted: 4/10/2015 by Bryan Hayes, PharmD
Click here to contact Bryan Hayes, PharmD
In addition to the down regulation of GABA receptors in chronic ethanol users, there is an upregulation in NMDA receptor subtypes. Although the pathophysiology is much more complex, when ethanol abstinence occurs, there is a shortage of GABA-mediated CNS inhibition and a surplus of glutamate-mediated CNS excitation. If GABA agonists are the mainstay of treatment, why not also target the NMDA receptor? Enter ketamine.
Only one study exists and was published recently.
While the dexmedetomidine studies should not be using reduction in benzodiazepine requirements as an endpoint, it may be acceptable for ketamine since it actually works on the underlying pathophysiology. More studies are needed but it's good to see we’re starting to look at it.
Wong A, et al. Evaluation of adjunctive ketamine to benzodiazepines for management of alcohol withdrawal syndrome. Ann Pharmacother 2015;49(1):14-9. [PMID 25325907]
Follow me on Twitter (@PharmERToxGuy) or Google Plus (+bryanhayes13)
Download the UMEM Pearls App!
Subscribe to daily UMEM Pearls (FREE!) via: